Hepatitis C virus: From oxygen free radicals to hepatocellular carcinoma

Journal of Viral Hepatitis

Volumn 14, Issue 12, 2007, Pages 821-829

  Farinati, F ^a,c   Cardin, R ^a   Bortolami, M ^a   Burra, P ^a   Russo, F P ^a   Rugge, M ^a   Guido, M ^a   Sergio, A ^b   Naccarato, R ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Venetian Institute of Oncology (IOV)   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Cytokines; Hepatitis C virus; Hepatocellular carcinoma; Oestrogens; Oncogenes; Oxidative DNA damage

Indexed keywords

CYTOKINE; ESTROGEN; ESTROGEN RECEPTOR; OXYGEN RADICAL; SEX HORMONE;

APOPTOSIS; CARCINOGENESIS; CELL PROLIFERATION; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DATA ANALYSIS; DNA DAMAGE; ENZYME ACTIVITY; GENE ACTIVATION; GENOMIC INSTABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFLAMMATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER INJURY; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; REVIEW; RISK FACTOR; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; CYTOKINES; DNA DAMAGE; GONADAL STEROID HORMONES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 36749092354     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00878.x     Document Type: Review

References (108)

1. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997 26 (Suppl. 1 15S 20S.
2. Anzola M. Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat 2002 11 : 383 393.
3. Chiaramonte M, Stroffolini T, Vian A et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999 85 : 2132 2137.
4. Kwun HJ, Jang KL. Dual effects of hepatitis C virus core protein on the transcription of cyclin-dependent kinase inhibitor p21 gene. J Viral Hepat 2003 10 (4 249 255.
5. Yamanaka T, Kodama T, Doi T. Subcellular localization of HCV core protein regulates its ability for p53 activation and p21 suppression. Biochem Biophys Res Commun 2002 294 (3 528 534.
6. Alisi A, Giambartolomei S, Cupelli F et al. Physical and functional interaction between HCV core protein and the different p73 isoforms. Oncogene 2003 22 (17 2573 2580.
7. Majumder A, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 2001 75 (3 1401 1407.
8. Arima N, Kao CY, Licht T et al. Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A. J Biol Chem 2001 276 (16 12675 12684.
9. Boyault S, Rickman DS, de Reyniès A et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007 45 : 42 52.
10. Honda M, Yamashita T, Ueda T et al. Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C. Hepatology 2006 44 : 1122 1138.
11. Fantone JC, Ward PA. Role of oxygen-derived free radicals and metabolites in leukoeyte-dependent inflammatory reactions. Am J Pathol 1982 107 : 397 418.
12. Onori L, Natali L, Frieri G, Caprilli R. The putative role of reactive oxygen species in gastrointestinal diseases. Ital J Gastroenterol 1983 25 : 324 335.
13. Lieber CS, de Carli LM. Hepatotoxicity of ethanol. J Hepatol 1991 12 : 394 401.
14. Greenstock CL. Free radical processes in radiation and chemical carcinogenesis. Adv Radiat Biol 1984 11 : 264 293.
15. Basaga HS. Biochemical aspects of free radicals. Biochem Cell Biol 1990 68 : 989 1008.
16. Cathcart R, Schwiers E, Saul RL, Ames BN. Thymine glycol and thymidine glycol in human and rat urine: a possible assay for oxidative DNA damage. Proc Natl Acad Sci U S A 1984 81 : 5633 5637.
17. Hollstein MC, Brooks P, Linn S, Ames BN. Hydroxymethyluracil DNA glycosylase in mammalian cells. Proc Natl Acad Sci U S A 1984 81 : 4003 4007.
18. Shigenaga MK, Gimeno CJ, Ames BN. Urinary 8-hydroxy-2′- deoxyguanosine as a biomarker of in vivo oxidative DNA damage. Proc Natl Acad Sci U S A 1989 86 : 9697 10001.
19. Marx J. Inflammation and cancer: the link grows stronger. Science 2004 306 : 966 1008.
20. Adelman R, Saul RL, Ames BN. Oxidative damage to DNA: relation to species metabolic rate and life span. Proc Natl Acad Sci U S A 1988 85 : 2706 2708.
21. Crawford D, Cerutti P. Expression of oxidant stress-related genes in tumor promotion of mouse epidermal cells JB6. In : Nygaard O, Simic M, Cerutti P, eds. Anticarcinogenesis and Radiation Protection. New York : Plenum Press, 1985 : 183 190.
22. Ames BN. Mutagenesis and carcinogenesis: endogenous and exogenous factors. Environ Mol Mutagen 1989 16 (Suppl. 66 77.
23. Troll W, Wiesner R. The role of oxygen radicals as a possible mechanism of tumor promotion. Annu Rev Pharmacol Toxicol 1985 25 : 509 528.
24. Kuchino Y, Mori F, Kasai H et al. Misreading of DNA templates containing 8-hydroxydeoxyguanosine at the modified base and at adjacent residues. Nature 1987 327 (6117 77 79.
25. Shinmura K, Yokota J. The OGG1 gene encodes a repair enzyme for oxidatively damaged DNA and is involved in human carcinogenesis. Antioxid Redox Signal 2001 3 (4 597 609.
26. Ide H, Kotera M. Human DNA glycosylases involved in the repair of oxidatively damaged DNA. Biol Pharm Bull 2004 27 (4 480 485.
27. Park EM, Shigenaga MK, Degan P et al. Assay of excised oxidative DNA lesions: isolation of 8-oxoguanine and its nucleoside derivatives from biological fluids with a monoclonal antibody column. Proc Natl Acad Sci U S A 1992 89 (8 3375 3379.
28. Farinati F, Cardin R, Degan P et al. Oxidative DNA damage in circulating leukocytes occurs as an early event in chronic HCV infection. Free Radic Biol Med 1999 27 (11-12 1284 1291.
29. Floyd RA, Watson JJ, Wong PK, Altmiller DH, Rickard RC. Hydroxyl free radical adduct of deoxyguanosine: sensitive detection and mechanisms of formation. Free Radic Res Commun 1986 1 (3 163 172.
30. Fraga CG, Shigenaga MK, Park JW, Degan P, Ames BN. Oxidative damage to DNA during aging: 8-hydroxy-2′deoxyguanosine in rat organ DNA and urine. Proc Natl Acad Sci U S A 1990 87 : 4533 4537.
31. Patel K, Zekrv A, McHutchison JG. Steatosis and chronic hepatitis C virus infection: mechanisms and significance. Clin Liver Dis 2005 9 (3 399 410.
32. Martens ME, Chang CH, Lee CP. Reye's syndrome: mitochondrial swelling and Ca2+ release induced by Reye's plasma, allantoin, and salicylate. Arch Biochem Biophys 1986 244 (2 773 786.
33. Murphy MG, Crocker JF, Her H. Abnormalities in hepatic fatty-acid metabolism in a surfactant/influenza B virus mouse model for acute encephalopathy. Biochim Biophys Acta 1996 1315 (3 208 216.
34. Farinati F, Cardin R, De Maria N et al. Iron storage, lipid peroxidation and glutathione tumover in chronic anti-HCV positive hepatitis. J Hepatol 1995 22 : 49 56.
35. De Maria N, Colantoni A, Fagiuoli S et al. Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radic Biol Med 1996 21 : 291 295.
36. Bellentani S, Pozzato O, Saccoccio O et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999 44 : 874 880.
37. Bellentani S, Tiribelli C, Saccoccio O et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology 1994 20 : 1442 1449.
38. Cardin R, Saccoccio G, Masutti F et al. DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease. Validation in an open population study. J Hepatol 2001 34 (4 587 592.
39. Puoti C, Magrini A, Stati T et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels (see comments). Hepatology 1997 26 : 1393 1398.
40. Persico M, Persico E, Suozzo R et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000 118 : 760 764.
41. Shimoda R, Nagashima M, Sakamoto M et al. Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis. Cancer Res 1994 54 : 3171 3172.
42. Koike K, Tsutsumi T, Fujie H, Shintani Y, Moriya K. Molecular mechanism of viral hepatocarcinogenesis. Oncology 2002 62 (Suppl. 1 29 37.
43. Ray RB, Lagging LM, Meyer K, Steele R. Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res 1995 37 : 209 220.
44. Ray RB, Lagging LM, Meyer K, Ray R. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J Virol 1996 70 : 4438 4443.
45. Sakamuro D, Furukawa T, Takegarni T. Hepatitis C nonstructural protein NS3 transforms N1H 3T3 cells. J Virol 1995 69 : 3893 3896.
46. Fujita T, Ishido S, Maramatsu S, Itoh M, Hotta H. Suppression of Actinomycin D-induced apoptosis by the NS3 protein of hepatitis C virus. Biochem Biophys Res Commun 1996 229 : 825 831.
47. Choi J, Ou JH. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 2006 290 : 847 851.
48. Abalea V, Cillard J, Dubos MP et al. Iron-induced oxidative DNA damage and its repair in primary rat hepatocyte culture. Carcinogenesis 1998 19 : 1053 1059.
49. Hsieh YH, Su IJ, Wang HC et al. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis 2004 25 (10 2023 2032.
50. Kitada T, Seki S, Iwai S et al. In situ detection of oxidative DNA damage, 8-hydroxydeoxyguanosine, in chronic human liver disease. J Hepatol 2001 35 (5 613 618.
51. Moriya K, Nakagawa K, Santa T et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001 61 (11 4365 4370.
52. Furutani T, Hino K, Okuda M et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006 130 (7 2087 2098.
53. Lee CM, Hung CH, Lu SN et al. Viral etiology of hepatocellular carcinoma and HCV genotypes in Taiwan. Intervirology 2006 49 (1-2 76 81.
54. Savvas SP, Koskinas J, Sinani C et al. Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece. J Viral Hepat 2002 12 (5 551 557.
55. Donato MF, Arosio E, Del Ninno E et al. High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity. Hepatology 2002 34 (3 523 528.
56. Dutta U, Kench J, Byth K et al. Hepatocellular proliferation and development of hepatocellular carcinoma: a case-control study in chronic hepatitis C. Hum Pathol 1998 29 (11 1279 1284.
57. Kumar D, Farrell GC, Kench J, George J. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol 2005 20 (9 1395 1400.
58. Rubbia-Brandt L, Quadri R, Abid K et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000 33 : 106 115.
59. Yuen MF, Wu PC, Lai VC, Lau JY, Lai CL. Expression of c-Myc, c-Fos, and c-jun in hepatocellular carcinoma. Cancer 2001 91 (1 106 112.
60. Farinati F, Cardin R, Bortolami M, Rugge M. The mechanisms underlying hepatitis C virus genotype 3-mediated liver damage. J Hepatol 2003 39 (2 292 294.
61. El-Omar EM, Rabkin CS, Gammon MD et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 2003 124 : 1193 1201.
62. Dai CY, Chuang WL, Lee LP et al. Associations of tumor necrosis factor alpha promoter polymorphisms at position -308 and -238 with clinical characteristics of chronic hepatitis C. J Viral Hepat 2006 13 (11 770 774.
63. Persico M, Capasso M, Persico E et al. Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. J Hepatol 2006 45 (6 779 785.
64. Russo MT, De Luca G, Degan P et al. Different DNA repair strategies to cambat the threat from 8-oxoguanine. Mutat Res 2007 614 : 69 76.
65. Cong WM, Zhang SH, Xian ZH, Wu WQ, Wu MC. Study on loss of heterozygosity and microsatellite instability in hepatocellular carcinoma. Zhonghua Bing Li Xue Za Zhi 2005 34 (2 71 74.
66. Ramadori G, Armbrust T. Cytokines in the liver. Eur J Gastroenterol Hepatol 2001 13 : 777 804.
67. Roberts RA, Kimber I. Cytokines in non-genotoxic hepatocarcinogenesis. Carcinogenesis 1999 20 : 1397 1401.
68. Zhu N, Khoshnan A, Schneider R et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol 1998 72 : 3691 3697.
69. Gochee PA, Jonsson JR, Clouston AD et al. Steatosis in chronic hepatitis C: association with increased messenger RNA expression of collagen I, tumor necrosis factor-alpha and cytochrome P450 2E1. J Gastroenterol Hepatol 2003 18 : 386 392.
70. Nelson DR, Lim HL, Marousis CG et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 1997 42 : 2487 2494.
71. Lapinski TW. The levels of IL-1beta, IL-4 and IL-6 in the serum and the liver tissue of chronic HCV-infected patients. Arch Immunol Ther Exp 2001 49 : 311 316.
72. Tanaka Y, Furuta T, Suzuki S et al. Impact of interleukin-1beta genetic polymorphisms on the development of hepatitis C virus-related hepatocellular carcinoma in Japan. J Infect Dis 2003 187 : 1822 1825.
73. Bahr MJ, Menuawy M, Boeker KH et al. Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C. Liver Int 2003 23 : 420 425.
74. Hoek JB, Pastorino JG. Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol 2002 27 : 63 68.
75. Tsutsumi T, Suzuki T, Moriya K et al. Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. Virology 2002 304 : 415 424.
76. Farinati F, Cardin R, Fiorentino M et al. Imbalance between cytoproliferation and apoptosis in hepatitis C virus related chronic liver disease. J Viral Hepat 2001 8 : 34 40.
77. Ikeguchi M, Hirooka Y. Expression of c-myc mRNA in hepatocellular carcinomas, noncancerous livers, and normal livers. Pathobiology 2004 71 : 281 286.
78. Chung YH, Kim JA, Song BC et al. Expression of transforming growth factor-alpha mRNA in livers of patients with chronic viral hepatitis and hepatocellular carcinoma. Cancer 2000 89 : 977 982.
79. Santoni-Rugiu E, Jensen MR, Factor VM, Thorgeirsson SS. Acceleration of c-myc-induced hepatocarcinogenesis by co-expression of Transforming Growth Factor (TGF)-α in transgenic mice is associated with TGF-β1 signaling disruption. Am J Pathol 1999 154 : 1693 1700.
80. Farinati F, Cardin R, Bortolami M, Guido M, Rugge M. Oxidative damage, pro-inflammatory cytokines, TGF-α and c-myc in chronic HCV-related hepatitis and cirrhosis. World J Gastroenterol 2006 12 (13 2065 2069.
81. Gramantieri L, Casali A, Trere D et al. Imbalance of IL-1 beta and IL-1 receptor antagonist mRNA in liver tissue from hepatitis C virus (HCV)-related chronic hepatitis. Clin Exp Immunol 1999 115 : 515 520.
82. Liu TZ, Lee KT, Chern CL et al. Free radical-triggered hepatic injury of experimental obstructive jaundice of rats involves overproduction of proinflammatory cytokines and enhanced activation of nuclear factor kappaB. Ann Clin Lab Sci 2001 31 : 383 390.
83. Thorgeirsson SS, Factor VM, Snyderwine EG. Transgenic mouse models in carcinogenesis research and testing. Toxicol Lett 2000 113 : 553 555.
84. Vermeulen K, Berneman ZN, Van Bockstaele DR. Cell cycle and apoptosis. Cell Prolif 2003 36 : 165 175.
85. Hironaka K, Factor VM, Calvisi DF, Conner EA, Thorgeirsson SS. Dysregulation of DNA repair pathways in a transforming growth factor alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis. Lab Invest 2003 83 : 643 654.
86. Lee TH, Tai DI, Cheng CJ et al. Enhanced nuclear factor-kappa B-associated Wnt-1 expression in hepatitis B- and C-related hepatocarcinogenesis: identification by functional proteomics. J Biomed Sci 2005 14 : 1 13.
87. Tien LT, Ito M, Nakao M et al. Expression of beta-catenin in hepatocellular carcinoma. World J Gastroenterol 2005 11 (16 2398 2401.
88. Ueta T, Ikeguchi M, Hirooka Y, Kaibara N, Terada T. Beta-catenin and cyclin D1 expression in human hepatocellular carcinoma. Oncol Rep 2002 9 (6 1197 2003.
89. Cui J, Zhou X, Liu Y, Tang Z, Romeih M. Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes. J Gastroenterol Hepatol 2003 18 (3 280 287.
90. Yanagitani A, Yamada S, Yasui S et al. Retinoic acid receptor alpha dominant negative form causes steatohepatitis and liver tumors in transgenic mice. Hepatology 2004 40 (2 366 375.
91. Oikawa S, Tada-Oikawa S, Kawanishi S. Site-specific DNA damage at the GGG sequence by UVA involves acceleration of telomere shortening. Biochemistry 2001 40 : 4763 4768.
92. Kyo S, Inoue M. Complex regulatory mechanisms of telomerase activity in normal and cancer cells: how can we apply them for cancer therapy? Oncogene 2002 21 : 688 697.
93. Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 2002 192 : 1 15.
94. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature 1997 389 (6648 300 305.
95. Farinati F, Cardin R, D'Errico A et al. Hepatocyte proliferative activity in chronic liver damage as assessed by the monoclonal antibody MIB1 Ki67 in archival material: the role of etiology, disease activity, iron and lipid peroxidation. Hepatology 1996 23 (6 1468 1475.
96. Gehrke SG, Stremmel W, Mathes I et al. Hemochromatosis and transferrin receptor gene polymorphisms in chronic hepatitis C: impact on iron status, liver injury and HCV genotype. J Mol Med 2003 81 (12 780 787.
97. Boada LD, Zumbado M, del RI et al. Steroid hormone progesterone induces cell proliferation and abnormal mitotic processes in rat liver. Arch Toxicol 2002 12 : 707 716.
98. Alvaro D, Alpini G, Onori P et al. Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. Gastroenterology 2002 119 (6 1681 1691.
99. Lee CH, Edwards AM. Stimulation of DNA synthesis and c-fos mRNA expression in primary rat hepatocytes by estrogens. Carcinogenesis 2001 22 (9 1473 1481.
100. Farinati F, De Maria N, Marafin C et al. Hepatocellular carcinoma in alcoholic cirrhosis: is sex hormone imbalance a pathogenetic factor? Eur J Gastroenterol Hepatol 1995 7 (2 145 150.
101. Farinati F, De Maria N, Fornasiero A et al. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig Dis Sci 1992 37 (5 659 662.
102. Farinati F. Tamoxifen treatment in hepatocellular carcinoma. Gastroenterology 1996 111 (1 272 274.
103. Perrone F, Gallo C, Daniele B et al. Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial. Curr Pharm Des 2002 8 (11 1013 1019.
104. Villa E, Camellini L, Dugani A et al. Variant liver estrogen and response to tamoxifen. Gastroenterology 1996 111 (1 271 272.
105. Villa E, Dugani A, Moles A et al. Variant liver estrogen receptor transcripts already occur at an early stage of chronic liver disease. Hepatology 1998 27 : 983 988.
106. Han X, Liehr JG. Microsome-mediated 8-hydroxylation of guanine bases of DNA by steroid estrogens: correlation of DNA damage by free radicals with metabolic activation to quinones. Carcinogenesis 1995 16 (10 2571 2574.
107. Altucci L, Addeo R, Cicatiello L et al. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 1996 12 (11 2315 2324.
108. Farinati F, Cardin R, Bortolami M et al. Estrogen receptors and oxidative damage in the liver. Mol Cell Endocrinol 2002 2 : 85 88.